Tag: ABBV-383
-
AbbVie’s Etentamig Cuts Progression or Death Risk by 60% in Phase 3 Multiple Myeloma Trial
AbbVie’s etentamig met both primary endpoints in the Phase 3 CERVINO trial, achieving a 74.0% objective response rate and reducing the risk of progression or death by 60% versus standard available therapies.
-
How Etentamig Redirects T Cells in Multiple Myeloma
Etentamig is a BCMA × CD3 bispecific T-cell engager designed with bivalent BCMA binding, low-affinity CD3 engagement and retained FcRn binding to redirect T cells against multiple myeloma cells.